Related Experiment Video
Updated: Oct 10, 2025
Culture and Imaging of Ex Vivo Organotypic Pseudomyxoma Peritonei Tumor Slices from Resected Human Tumor Specimens
Published on: December 9, 2022
Novel Perspectives in Pseudomyxoma Peritonei Treatment
Antonio Sommariva1, Marco Tonello1, Giulia Rigotto2
1Surgical Oncology of the Esophagus and Digestive Tract, Veneto Institute of Oncology IOV-IRCCS, 35100 Padua, Italy.
Abstract:
Pseudomyxoma Peritonei (PMP) is an anatomo-clinical condition characterized by the implantation of neoplastic cells on peritoneal surfaces with the production of a large amount of mucin. The rarity of the disease precludes the evaluation of treatment strategies within randomized controlled trials. Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) has proven to be the only therapeutic option with potential chances of cure and long-term disease control. The present review discusses the epidemiology, pathogenesis, clinical presentation and treatment of PMP, focusing on the molecular factors involved in tumor progression and mucin production that could be used, in the upcoming future, to improve patient selection for surgery and to expand the therapeutic armamentarium.
Insights
Pseudomyxoma Peritonei (PMP) is a rare condition involving neoplastic cells and mucin production. Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy offers the best chance for cure and long-term control.
Area of Science:
- Oncology
- Surgical Oncology
- Gastroenterology
Background:
- Pseudomyxoma Peritonei (PMP) is a rare condition characterized by neoplastic cell implantation and mucin production within the peritoneum.
- The rarity of PMP limits the ability to conduct randomized controlled trials for treatment evaluation.
Purpose of the Study:
- To review the epidemiology, pathogenesis, clinical presentation, and treatment of PMP.
- To explore molecular factors in PMP progression and mucin production for improved patient selection and therapeutic strategies.
Main Methods:
- Literature review of Pseudomyxoma Peritonei.
- Analysis of current treatment modalities, including Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
- Discussion of molecular targets for future therapies.
Main Results:
- Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is the primary curative treatment for PMP.
- Molecular factors influencing tumor progression and mucin production are key areas for future research.
Conclusions:
- CRS and HIPEC represent the most effective treatment for Pseudomyxoma Peritonei, offering potential for cure.
- Understanding molecular mechanisms is crucial for advancing PMP patient selection and treatment options.
More Related Videos
07:20Intraoperative Detection of Subtle Endometriosis: A Novel Paradigm for Detection and Treatment of Pelvic Pain Associated with the Loss of Peritoneal Integrity
Published on: December 21, 2012
08:01Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
Published on: April 21, 2022